GeneVentiv Therapeutics: Pioneering gene therapy for blood disorders, including universal treatment for hemophilias.
GeneVentiv Therapeutics, founded with a mission to revolutionize the treatment of blood disorders, is a pre-clinical gene therapy company. Their core vision is to transform lives through innovative gene therapies. The company's flagship product, GENV-HEM, is the first universal gene therapy for hemophilias A and B, designed to work with or without inhibitors. Additionally, they are developing a gene therapy for Hemophilia Arthropathy, a degenerative joint disease. GeneVentiv primarily focuses on addressing unmet medical needs in the blood disorder market.
Notable affiliations include support from the National Hemophilia Foundation and an orphan drug designation from the FDA for GENV-HEM. The company has made significant strides in the gene therapy field, positioning itself as a pioneer in treating hemophilia through a single infusion, AAV-based approach. These achievements underscore GeneVentiv's potential impact on improving the quality of life for individuals with blood disorders, marking it as a key player in the biopharmaceutical industry.
GeneVentiv Therapeutics' most recent funding round was for $1.4M (USD) in August 2022.
As of Aug 17, 2022, GeneVentiv Therapeutics has disclosed funding of $1.4M (USD).

Jaguar Gene Therapy

Remedium Bio
remedium-bio.com

NabGen
nabgen.com

Orphion Therapeutics

Apertura Gene Therapy
aperturagtx.com

Genascence
genascence.com

AAVogen
aavogen.com

Forge Biologics
forgebiologics.com

Bedrock Therapeutics

Rampart Bioscience
rampartbio.com

Regenxbio
regenxbio.com
Genecure
genecure.com

Code Biotherapeutics
codebiotx.com

Regel Therapeutics

American Gene Technologies International
americangene.com

Excision BioTherapeutics

XyloCor Therapeutics
xylocor.com

Affinia Therapeutics
affiniatx.com

Limelight Bio
limelightbio.com

Frontera Therapeutics